Holen Sie sich die Stockscreener-App
4.74
3.95%
0.18
Schlusskurs vom Vortag:
$4.56
Offen:
$4.562
24-Stunden-Volumen:
101.28K
Relative Volume:
1.15
Marktkapitalisierung:
$90.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.63M
KGV:
-2.4786
EPS:
-1.9124
Netto-Cashflow:
$-47.63M
1W Leistung:
+3.72%
1M Leistung:
+0.21%
6M Leistung:
+20.92%
1J Leistung:
+43.20%
1-Tages-Spanne:
$4.56
$4.83
1-Wochen-Bereich:
$4.5001
$4.83
52-Wochen-Spanne:
$3.06
$5.21
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.74 | 90.89M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst - AD HOC NEWS
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PYPD Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineNew Analyst Coverage - newsline.com
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PolyPid Ltd. (PYPD) Shares Edge Higher as Support Holds, Resistance in FocusTRIN Signal - newsline.com
PYPD Technical Analysis & Stock Price Forecast - Intellectia AI
PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com - Investing.com Nigeria
PolyPid Sets July 15, 2026 Shareholder Meeting to Vote on Board, Auditor and Equity Grants - TipRanks
PolyPid schedules annual and extraordinary shareholder meeting for July 15 - Investing.com India
PolyPid (PYPD) schedules July 15, 2026 meeting on director, auditor and option approvals - Stock Titan
When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)? - simplywall.st
PYPD Q1 2026 Earnings: Narrower-than-Expected Loss Drives 20.81% Surprise; Shares Dip Despite ProgressForward EPS Estimate - newsline.com
PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27Factor Valuation - newsline.com
PYPD Q1 2026 Earnings: Pre-Revenue Biotech Narrows Loss, Stock Slides on No Commercial MilestonesQuarterly Financial Update - newsline.com
PolyPid Stock Barely Moves After FDA Filing, But a 2027 Decision Now Looms - Bez Kabli
PYPD Q1 2026 Earnings: Narrower Loss Surprises as Key Pipeline Progress Remains on TrackGuidance Accuracy Score - newsline.com
PYPD Q1 2026 Earnings: Narrower Than Expected Loss Drives Positive Surprise Despite Stock DipEarnings Revision Downgrade - newsline.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD) - The Globe and Mail
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100 - marketscreener.com
PolyPid Files NDA with FDA for Lead Infection-Prevention Drug D-PLEX100 - TipRanks
PolyPid completes NDA submission for surgical infection drug - Investing.com
PolyPid completes NDA submission for surgical infection drug By Investing.com - Investing.com Canada
PolyPid (Nasdaq: PYPD) files FDA NDA for D-PLEX100 infection drug - Stock Titan
New surgical infection drug from PolyPid heads to FDA decision in 2027 - Stock Titan
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ - GlobeNewswire
PolyPid Ltd stock (US70450B1035): Nasdaq-listed biotech sees quiet trading as investors await next c - AD HOC NEWS
PYPD Q1 2026 Earnings: Narrower Net Loss Beats Expectations as Clinical Pipeline AdvancesFinancial Data - The Legal Advocate
PolyPid Ltd. (PYPD) Q1 2026 Earnings: Narrower-than-Expected Loss on Strong Expense ControlMargin Guidance - The Legal Advocate
PolyPid Ltd. (PYPD) Edges Lower, Testing Key Support Near $4.52Delta Hedging - The Legal Advocate
PYPD Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesGuidance vs Actual - The Legal Advocate
PolyPid Shares Edge Lower as Stock Nears Key Support ZoneShort Term Trading Ideas - The Legal Advocate
PolyPid Shares Slide Amid Light Trading, Testing Key Support Levels (PYPD)Market Cap Weight - The Legal Advocate
PolyPid Q1 earnings call highlights - MSN
PolyPid (PYPD) Jumps 3.93% as Stock Approaches Key Resistance LevelSupport Level Bounce - Newser
PYPD Q1 2026 Earnings: EPS Beat on Operational Discipline, But Revenue Remains AbsentEarnings Season Review - Newser
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - GlobeNewswire
PolyPid’s Earnings Call Signals Tightrope to Approval - TipRanks
PolyPid Ltd stock (US70450B1035): pivotal Phase 3 data and Nasdaq listing shift in focus - AD HOC NEWS
PolyPid Submits D-PLEX100 New Drug Application to FDA - HarianBasis.co
PolyPid Ltd.Ordinary Shares (NQ: PYPD - FinancialContent
PolyPid stock (US70450B1035): NDA submission advances D-PLEX100 toward FDA review - AD HOC NEWS
PolyPid Ltd. (NASDAQ:PYPD) Q1 2026 Earnings Call Transcript - Insider Monkey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
PYPD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):